Details of the Drug Combination

General Information of Drug Combination (ID: DCVFZJP)

Drug Combination Name
Cyclosporin A Marizomib
Indication
Disease Entry Status REF
Diffuse intrinsic pontine glioma Investigative [1]
Component Drugs Cyclosporin A   DMUYKBZ Marizomib   DME9QGW
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL
High-throughput Screening Result Testing Cell Line: DIPG25
Zero Interaction Potency (ZIP) Score: 8.21
Bliss Independence Score: 7.72
Loewe Additivity Score: 8.76
LHighest Single Agent (HSA) Score: 12.14

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Cyclosporin A
Disease Entry ICD 11 Status REF
Adult acute monocytic leukemia N.A. Approved [2]
Bronchiolitis obliterans syndrome N.A. Approved [3]
Large granular lymphocytic leukemia 2A90.1 Approved [4]
Leukemia N.A. Approved [5]
Lupus nephritis 4A40.0Y Approved [6]
Myeloid leukaemia 2B33.1 Approved [7]
Psoriasis EA90 Approved [8]
Xerophthalmia 5B55.Y Approved [9]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 1 [10]
Corneal disease 9A78.Z Investigative [11]
Indication(s) of Marizomib
Disease Entry ICD 11 Status REF
Glioblastoma of brain 2A00.00 Phase 3 [12]
Malignant glioma 2A00.0 Phase 1 [13]
Multiple myeloma 2A83 Phase 1 [13]
Solid tumour/cancer 2A00-2F9Z Phase 1 [14]
Marizomib Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Proteasome (PS) TTU7ZMG NOUNIPROTAC Inhibitor [15]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Clinical and biological impact of ATP-binding cassette transporter activity in adult acute myeloid leukemia. Haematologica. 2023 Jan 1;108(1):61-68.
3 Bronchiolitis obliterans syndrome is associated with increased senescent lymphocytes in the small airways. J Heart Lung Transplant. 2021 Feb;40(2):108-119.
4 Rituximab for rheumatoid arthritis-associated large granular lymphocytic leukemia, a retrospective case series. Semin Arthritis Rheum. 2020 Oct;50(5):1109-1113.
5 Cyclosporin A protects JEG-3 cells against oxidative stress-induced apoptosis by inhibiting the p53 and JNK/p38 signaling pathways. Reprod Biol Endocrinol. 2020 Oct 12;18(1):100.
6 Efficacy and safety of Iguratimod as an add-on therapy for refractory lupus nephritis: A preliminary investigational study. Front Immunol. 2023 Mar 8;14:1062919.
7 Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol. 2024 Feb;11(2):e127-e135.
8 Pustular psoriasis. Cutis. 1993 Jan;51(1):29-32.
9 Cyclosporin A (CyA) in primary Sj?gren's syndrome: a double blind study. Ann Rheum Dis. 1986 Sep;45(9):732-5.
10 Why Choose Cyclosporin A as First-line Therapy in COVID-19 Pneumonia. Reumatol Clin. 2020 Apr 16;S1699-258X(20)30044-9.
11 Anti-inflammatory therapy of dry eye. Ocul Surf. 2003 Jan;1(1):31-6.
12 ClinicalTrials.gov (NCT03345095) A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma (MIRAGE). U.S. National Institutes of Health.
13 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
14 Clinical pipeline report, company report or official report of Triphase Accelerator .
15 Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets. 2011 Mar;11(3):254-84.